The Market Reports

Synopsis
The global market for Human Microbiome was estimated to be worth US$ 568 million in 2024 and is forecast to a readjusted size of US$ 3351 million by 2031 with a CAGR of 30.5% during the forecast period 2025-2031.
The Human Microbiome refers to the collective microorganisms and their genetic material residing in various parts of the human body, such as the gut, skin, mouth, respiratory tract, and reproductive system. These microbes form a symbiotic relationship with the human host, playing critical roles in immune modulation, nutrient absorption, metabolic regulation, and disease prevention. With the advancement of high-throughput sequencing, synthetic biology, and artificial intelligence, the commercialization of the microbiome is shifting from basic research toward precision medicine, immunotherapy, probiotics, functional foods, and personalized nutrition. The global human microbiome industry is now entering an accelerated application phase, becoming a model for cross-border integration across healthcare, biotechnology, and nutrition sectors, and attracting major pharmaceutical and biotech companies, as well as emerging startups.
The human microbiome sector has gained momentum due to rising demand for precision medicine, chronic disease management, and alternatives to antibiotics. Increasing evidence from Phase III clinical trials supports the role of gut microbiota in conditions such as cancer, neurological disorders, and autoimmune diseases, accelerating product development in therapeutics, diagnostics, and nutritional interventions. The U.S. and EU have included microbiome initiatives in their national-level precision medicine strategies, and investor interest continues to surge. The global market for microbiome therapeutics is projected to surpass $10 billion by 2030.
Despite the promising outlook, the industry faces significant hurdles. These include individual microbiome variability leading to inconsistent treatment efficacy, lack of standardized clinical validation pathways, and regulatory uncertainty. Technological challenges around scalable manufacturing, storage, activity control, and genomic safety further complicate commercialization. Additionally, public acceptance, ethical concerns, and low physician familiarity with microbiome-based therapies present barriers to market expansion.
Downstream, pharmaceutical, nutritional, and diagnostic companies are accelerating commercialization of microbiome-related products. There is growing demand for gut microbiome therapeutics, fecal microbiota transplantation (FMT), probiotics, and next-generation probiotics (NGPs), particularly in cancer support therapy, autism management, and inflammatory bowel disease. Rising consumer awareness of microbiome balance is also fueling demand in functional food and personalized nutrition, turning the sector into a hotbed for venture capital and strategic investment.
This report aims to provide a comprehensive presentation of the global market for Human Microbiome, focusing on the total sales revenue, key companies market share and ranking, together with an analysis of Human Microbiome by region & country, by Type, and by Application.
The Human Microbiome market size, estimations, and forecasts are provided in terms of sales revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Human Microbiome.
Market Segmentation
By Company
Vedanta
Seres Therapeutics
Second Genome
Rebiotix
ActoGeniX
Enterome BioScience
AvidBiotics
4D Pharma Research Ltd
Enterologics
Metabogen
Metabiomics
Ritter Pharmaceuticals
Osel
Symberix
Miomics
Symbiotix Biotherapies
MicroBiome Therapeutics LLC
Segment by Type
Gastrointestinal Tract Human Micobiome
Urogenital Tract Human Micobiome
Others
Segment by Application
Treatment
Diagnosis
By Region
North America
United States
Canada
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia-Pacific
Europe
Germany
France
U.K.
Italy
Netherlands
Nordic Countries
Rest of Europe
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, global total market size. This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 2: Detailed analysis of Human Microbiome company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Revenue of Human Microbiome in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 6: Revenue of Human Microbiome in country level. It provides sigmate data by Type, and by Application for each country/region.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.
Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 9: Conclusion.

Index